Prof Facon discusses the IMROZ study with ecancer at ASCO 2024. He notes that it is the first phase 3 study of an anti-CD38 monoclonal antibody versus standard of care (bortezomib, lenalidomide, and dexamethasone) in this patient population to show a significantly reduced risk of progression or death.

The safety profile was consistent with the addition of isatuximab to bortezomib, lenalidomide, and dexamethasone. Numerical differences in adverse events are largely explained by longer exposure in the isatuximab arm.

Prof Facon suggests that these results support isatuximab combined with bortezomib, lenalidomide, and dexamethasone as a potential new standard of care in newly diagnosed multiple myeloma patients not intended for transplant.